Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Life Sci
; 248: 117477, 2020 May 01.
Article
in English
| MEDLINE | ID: covidwho-2799
ABSTRACT
AIMS:
A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). MATERIALS ANDMETHODS:
In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. KEYFINDINGS:
The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.SIGNIFICANCE:
The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
Ribavirin
/
Viral Proteins
/
RNA-Dependent RNA Polymerase
/
Adenosine Monophosphate
/
Coronavirus Infections
/
Guanosine Monophosphate
/
Alanine
/
Sofosbuvir
Language:
English
Journal:
Life Sci
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS